The drugs for arthritis and heart disease can also treat COVID-19?
- Normal Liver Cells Found to Promote Cancer Metastasis to the Liver
- Nearly 80% Complete Remission: Breakthrough in ADC Anti-Tumor Treatment
- Vaccination Against Common Diseases May Prevent Dementia!
- New Alzheimer’s Disease (AD) Diagnosis and Staging Criteria
- Breakthrough in Alzheimer’s Disease: New Nasal Spray Halts Cognitive Decline by Targeting Toxic Protein
- Can the Tap Water at the Paris Olympics be Drunk Directly?
The drugs for arthritis and heart disease can also treat COVID-19?
- Should China be held legally responsible for the US’s $18 trillion COVID losses?
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
The drugs for arthritis and heart disease can also treat COVID-19?
According to a Reuters report on September 10, researchers recently discovered that an anti-inflammatory drug, Anakinra, used to treat rheumatoid arthritis, static disease and recurrent fever, can significantly reduce severe illness. The risk of death in patients with COVID-19.
The research results have been published in the top academic journal “Nature Medicine” (impact factor of 36.130 in 2019). Researchers found that among 594 patients with COVID-19, compared with patients taking placebo, the risk of death for those receiving anakinra treatment was generally reduced by 55% to 80%.
(Picture from Nature Medicine)
“From the 14th day, the clinical benefits of anakinra treatment have been very obvious, and the benefits of the drug can continue until the 28th day,” but the researchers pointed out that the use of anakinra to guide the COVID-19 Treatment may be problematic because not every hospital can provide tests for related drugs.
In addition, new data shows that drugs that usually prevent thrombosis after arterial clearing surgery can also prevent thrombosis in patients with COVID-19 disease-an article was published in the academic journal “Science Advances” on September 8. (The impact factor for 2020 is 14.14) The paper stated that the anticoagulant drugs clopidogrel and ticagrelor can effectively prevent the excessive activation of platelets in patients with COVID-19 disease to form thrombus.
(Picture from Science Advances)
According to Reuters, Bristol-Myers Squibbl and Sanofi are currently selling clopidogrel under the trade name Plavix. And AstraZeneca has already started selling Tegrelor under the brand name Brilinta.
The author of the paper said that if more studies can prove this discovery, these drugs may “become a particularly attractive therapy for reducing inflammatory thrombosis caused by the new coronavirus.”
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.